logo-loader
RNS
Truetide plc

Truetide PLC - Investment Update - Paraytec HoT with VosBio

RNS Number : 6508J
Truetide PLC
25 June 2026
 

25 June 2026

Truetide plc

("Truetide", the "Company" or the "Group")

 

Investment update - Paraytec agrees heads of terms for proposed collaboration agreement with VosBio Inc.

 

Truetide plc (AIM: TRUE) announces that its 100%-owned investee company, Paraytec Limited ("Paraytec"), has agreed heads of terms for a proposed research and development collaboration agreement with VosBio, Inc. ("VosBio"), a US-based developer of non-invasive breath-sampling technology, to evaluate the feasibility of combining their respective technologies in the field of early, non-invasive lung cancer detection.

 

VosBio has developed the Universal Breath Collector, a device for the rapid, non-invasive capture of exhaled breath condensate ("EBC") from human subjects. VosBio has identified extracellular vesicles ("EVs") in EBC at concentrations which it believes are comparable to those found in sputum and holds data indicating that EV profiles may have the potential to differ between healthy individuals and lung cancer patients. VosBio has filed patent applications covering the counting, characterisation and ratio analysis of EVs in this context.

 

Paraytec's CX300 is a portable, high-sensitivity fluorescence detection instrument capable of identifying labelled biomarkers at picomolar concentrations. Paraytec and VosBio intend to assess whether the CX300, combined with VosBio's breath-collection technology, can support an integrated, non-invasive test for biomarkers associated with early-stage lung cancer.

 

VosBio maintains an existing fee-funded research collaboration with the University of Sheffield involving cell and EV-based exhaled breath analysis. Subject to entering into the definitive collaboration agreement, the proposed partnership with Paraytec is structured to test commercial and scientific viability before any further investment of Group resources is committed.

 

The Board believes that combining the CX300's detection sensitivity with VosBio's non-invasive breath-sampling approach represents a logical extension of Paraytec's existing capability and could support the development of a clinically relevant screening or triage application. Lung cancer remains the leading cause of cancer death worldwide, in large part because the majority of cases are diagnosed at a late stage; a validated, non-invasive screening or triage tool would address a substantial unmet clinical need.

 

Further announcements will be made in due course once the definitive collaboration agreement has been signed.

 

Trevor Brown, CEO of Truetide, said: "This proposed collaboration with VosBio provides a further opportunity for Paraytec to apply its CX300 platform to an area of significant unmet clinical need in early cancer screening. Importantly, the initial work is being funded by VosBio and is structured as a disciplined feasibility programme, enabling us to assess the scientific and commercial potential before committing further Group resources. We will update shareholders as the programme progresses."

 

 

For further information:

 

Truetide plc

Tel: 01738 587555

Trevor Brown, Chief Executive Officer

Viv Hallam, Executive Director




Allenby Capital Limited (Nominated Adviser and Joint Broker)

Tel: 020 3328 5656

James Reeve / Ashur Joseph




AlbR Limited (Joint Broker)

Tel: 020 7469 0936

Duncan Vasey / Lucy Williams


 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PFUBRGDLBBDDGLS
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read